Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3109/02841866509133089 | DOI Listing |
Brachytherapy
January 2025
Department of Radiology, The Second People's Hospital of China Three Gorges University, Yichang, Hubei, China. Electronic address:
Objective: The objective of this study was to evaluate the efficacy and safety of TACE combined with 125I seeds (TACE-125I) in the treatment of recurrent HCC at complex sites after hepatectomy.
Methods: This study retrospectively analyzed the clinical data of recurrent HCC patients located at complex sites (such as large blood vessels, diaphragm dome, etc.) after hepatectomy from January 2012 to December 2023, all of whom received TACE-125I or TACE therapy.
Int J Nanomedicine
January 2025
Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China.
Purpose: None of the antibody-drug conjugates (ADCs) targeting Claudin 18.2 (CLDN18.2) have received approval from regulatory authorities due to their limited clinical benefits.
View Article and Find Full Text PDFMedicine (Baltimore)
January 2025
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Rationale: We report here a case of using iodine-125 (125I) seed implantation via endobronchial ultrasound (EBUS) in the treatment of malignant central airway obstruction (MCAO) in a patient with lung adenocarcinoma.
Patient Concerns: The patient still experienced MCAO after conventional bronchoscopic interventional therapy.
Diagnoses: The patient was diagnosed as lung adenocarcinoma stage IV (T4N2M1a).
Brachytherapy
January 2025
Department of Radiology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of life Sciences and Medicine, University of Science and Technology, Hefei, Anhui 230022, PR China. Electronic address:
Purpose: To compare the effectiveness and safety of CT-guided iodine-125 seed brachytherapy in conjunction with chemotherapy against chemotherapy alone for the management of intermediate and advanced non-small cell lung cancer (NSCLC) lacking oncogenic driving genes.
Methods And Materials: Retrospective analysis was conducted on clinical data from 128 patients diagnosed with intermediate and advanced non-small cell lung cancer who received iodine-125 combined with chemotherapy or chemotherapy alone due to the absence of oncogenic driver gene mutations. The patients in two groups were compared at 6-month follow-up for objective remission rate (ORR), Disease control rate (DCR), local progression-free survival (LPFS), overall survival (OS), clinical symptom improvement, and adverse events.
Phys Med Biol
January 2025
Department of Medical Physics, Jeroen Bosch Ziekenhuis, Henri Dunantstraat 1, 's-Hertogenbosch, 5223GZ, NETHERLANDS.
The treatment of breast cancer during pregnancy requires careful consideration of consequences for both maternal and fetal health. In non-pregnant patients, the use of radioactive iodine-125 (125I)-seeds is standard practice for localising non-palpable breast tumors before breast-conserving surgery. However, the use of 125I-seeds in pregnant patients has been avoided due to concerns about fetal radiation exposure.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!